1. Search Result
Search Result
Isoforms Recommended: STAT3
Results for "

STAT-3

" in MedChemExpress (MCE) Product Catalog:

332

Inhibitors & Agonists

1

Screening Libraries

1

Fluorescent Dye

2

Biochemical Assay Reagents

15

Peptides

1

Inhibitory Antibodies

104

Natural
Products

3

Recombinant Proteins

14

Isotope-Labeled Compounds

5

Antibodies

1

Click Chemistry

7

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-150603

    STAT Apoptosis Bcl-2 Family Cancer
    STAT3-IN-13 (compound 6f) is a potent STAT3 inhibitor. STAT3-IN-13 has anti-proliferative effects and binds to the STAT3 SH2 domain with a KD of 0.46 μM. STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705 and downstream target gene expression. STAT3-IN-13 induces apoptosis in vitro and suppresses the growth and metastasis of tumor in vivo. STAT3-IN-13 can be used for cancer research .
    STAT3-IN-13
  • HY-128588
    STAT3-IN-3
    5+ Cited Publications

    STAT Apoptosis Cancer
    STAT3-IN-3 is a potent and selective inhibitor of signal transducer and activator of transcription 3 (STAT3), with anti-proliferative activity. STAT3-IN-3 induces apoptosis in breast cancer cells. STAT3-IN-3 acts as a promising mitochondria-targeting STAT3 inhibitor for cancer research .
    STAT3-IN-3
  • HY-150251

    STAT PROTACs Cancer
    STAT3 degrader-2 is a PROTAC-based degrader of STAT3. STAT3 degrader-2 can degrade the level of total STAT3 protein. STAT3 degrader-2 can be used for the research of cancer and other diseases . STAT3 degrader-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    STAT3 degrader-2
  • HY-147048

    STAT Cancer
    STAT3 degrader-1 (compound 295) is a potent STAT3 degrader. STAT3 degrader-1 can be used for researching anticancer . STAT3 degrader-1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    STAT3 degrader-1
  • HY-P10114

    PpYLKTK-mts; STAT3 PI

    STAT Cancer
    STAT3-IN-24, cell-permeable (PpYLKTK-mts) is a STAT3 peptide inhibitor. STAT3-IN-24, cell-permeable inhibits recruitment of STAT3 to Jak2 and phosphorylation of Y705, thus preventing the dimerization and the nuclear translocation of STAT3 .
    STAT3-IN-24, cell-permeable
  • HY-RS13888

    Small Interfering RNA (siRNA) Others

    STAT3 Human Pre-designed siRNA Set A contains three designed siRNAs for STAT3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    STAT3 Human Pre-designed siRNA Set A
    STAT3 Human Pre-designed siRNA Set A
  • HY-RS13889

    Small Interfering RNA (siRNA) Others

    Stat3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Stat3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Stat3 Mouse Pre-designed siRNA Set A
    Stat3 Mouse Pre-designed siRNA Set A
  • HY-RS13890

    Small Interfering RNA (siRNA) Others

    Stat3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Stat3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Stat3 Rat Pre-designed siRNA Set A
    Stat3 Rat Pre-designed siRNA Set A
  • HY-112447

    STAT Cancer
    STAT3-IN-5 is a potent STAT3 inhibitor. STAT3-IN-5 inhibits STAT3-Y705 phosphorylation with an EC50 value of 170 nM. STAT3-IN-5 inhibits cytokine induced JAK activation. STAT3-IN-5 induces apoptosis. STAT3-IN-5 can be used in research of cancer .
    STAT3-IN-5
  • HY-N10472

    STAT Cancer
    STAT3-IN-14 (Compound 1) is a STAT3 inhibitor and has STAT3 phosphorylation inhibitory activity. STAT3-IN-14 (Compound 1) can directly bind to the hinge region of STAT3 .
    STAT3-IN-14
  • HY-162607

    STAT Inflammation/Immunology
    STAT3-IN-28 (compound 18) is a STAT3 inhibitor. STAT3-IN-28 can inhibit the activation of microglia and has anti-neuroinflammatory effects. STAT3-IN-28 can cross the blood-brain barrier .
    STAT3-IN-28
  • HY-146728

    STAT Apoptosis Cancer
    STAT3-IN-10 is a STAT3 inhibitor with an IC50 value of 5.18 µM. STAT3-IN-10 directly binds to STAT3 SH2 domain, induces cancer cells apoptosis .
    STAT3-IN-10
  • HY-146666

    Apoptosis STAT Cancer
    STAT3-IN-9 is a potent STAT3 inhibitor. STAT3-IN-9 inhibits the activation of STAT3 (Tyr705) without influencing the phosphorylation of STAT1 (Tyr701). STAT3-IN-9 induces apoptosis and cell cycle arrest at the G2/M phase .
    STAT3-IN-9
  • HY-144871

    STAT Cancer
    STAT3-IN-8 (compound H172) is a potent STAT3 inhibitor. STAT3-IN-8 has the potential for cancer research .
    STAT3-IN-8
  • HY-155982

    STAT Cancer
    STAT3-IN-20 (Compound 40) is a selective STAT3 inhibitor (IC50: 0.65 μM). STAT3-IN-20 binds the SH2 domain to inhibit STAT3 phosphorylation, translocation, and downstream gene transcription. STAT3-IN-20 exhibits antiproliferative activities against STAT3-overactivated DU145 and MDA-MB-231 cancer cells (IC50: 2.97 μM and 3.26 μM respectively). STAT3-IN-20 induces cell cycle arrest and apoptosis .
    STAT3-IN-20
  • HY-168043

    STAT Cancer
    STAT3-IN-35 is a STAT3 inhibitor that binds to SH2 domain. STAT3-IN-35 inhibits the phosphorylation of STAT3 and possesses antiproliferative activities against triple-negative breast cancer (TNBC) cell lines. STAT3-IN-35 also has a toxicity and potent antitumor activity in a TNBC xenograft model .
    STAT3-IN-35
  • HY-151976
    STAT3-IN-15
    1 Publications Verification

    STAT Inflammation/Immunology
    STAT3-IN-15 is a potent and orally active STAT3 inhibitor against idiopathic pulmonary fibrosis (IPF). STAT3-IN-15 inhibits STAT3 phosphorylation. STAT3-IN-15 also inhibits the migration and deformation of epithelial cells induced by TGF-β1 and inhibit epithelial-mesenchymal transition (EMT) .
    STAT3-IN-15
  • HY-P10113

    STAT Cancer
    STAT3-IN-23 (PY*LKTK) is a potent STAT3 inhibitor .
    STAT3-IN-23
  • HY-161644

    STAT Apoptosis Cancer
    STAT3-IN-27 (Compound 41) is an orally active inhibitor for phosphorylation of STAT3 (KD is 4.4 μM) and STAT3 transcription (IC50 is 22.57 nM). STAT3-IN-27 inhibits proliferation of various cancer cells with IC50 of 10-500 nM. STAT3-IN-27 arrests the cell cycle at G2/M phase, induces mitochondrial dysfunction and apoptosis in HCT116, inhibits cell migration of HCT116. STAT3-IN-27 exhibits antitumor efficacy in mouse model .
    STAT3-IN-27
  • HY-149007
    STAT3-IN-11
    1 Publications Verification

    STAT Apoptosis Cancer
    STAT3-IN-11 (7a) is a selective STAT3 inhibitor that inhibits the phosphorylation of STAT3 at site pTyr705. STAT3-IN-11 inhibits the phosphorylation of downstream genes (Survivin and Mcl-1) without affecting its upstream tyrosine kinases (Src and JAK2) levels and p-STAT1 expression. STAT3-IN-11 can induce cancer cell apoptosis, which is potential for the discovery of effective STAT3 inhibitors and antitumor agents against cancers .
    STAT3-IN-11
  • HY-144870

    STAT Cancer
    STAT3-IN-7, an aryl sulfonamido azetidine compound, is an orally active STAT3 inhibitor. STAT3-IN-7 has anticancer activities (WO2021016333A1, H182) .
    STAT3-IN-7
  • HY-150538

    STAT Apoptosis Cancer
    STAT3-IN-12 is a potent STAT3 signal inhibitor that can inhibit IL-6 induced JAK/STAT3 signalling pathway activation. STAT3-IN-12 inhibits cancer cell growth, migration, and induce cell apoptosis as well as cycle arrest. STAT3-IN-12 can be used in cancer-related research, such as hepatocellular carcinoma (HCC) and oesophageal carcinoma .
    STAT3-IN-12
  • HY-169007

    STAT Inflammation/Immunology
    STAT3-IN-34 (Compound 15E) is an inhibitor for STAT3, and inhibits the nuclear translocation and transcriptional regulator activity of STAT3. STAT3-IN-34 inhibits the proliferation of cell HaCaT with IC50 of 0.008 μM. STAT3-IN-34 inhibits IL-17A expression and ameliorates Imiquimod (HY-B0180)-induced psoriasis in mice .
    STAT3-IN-34
  • HY-155808

    STAT JAK Apoptosis COX Cancer
    STAT3-IN-18 (compound SPP) is a platinum (IV) complex with an axial ligand derived from sandalwood. STAT3-IN-18 inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, with anti-proliferative activity. STAT3-IN-18 activates caspase-3 and increases cleaved polyADP-ribose polymerase to induce apoptosis. STAT3-IN-18 promotes maturation and antigen presentation of dendritic cells and demonstrates safety in vivo.
    STAT3-IN-18
  • HY-160496

    STAT Cancer
    STAT3-IN-25 (compound 2p) is a potent STAT3 inhibitor with a p-trifluoroethoxy benzyl substituent. STAT3-IN-25 shows STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 22.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 32.5 nM. STAT3-IN-25 shows potent antiproliferation activities on BxPC-3 and Capan-2 cells. STAT3-IN-25 has the potential for pancreatic cancer research .
    STAT3-IN-25
  • HY-164445

    STAT Cancer
    STAT3-IN-32 (compound 2p) is an orally active, potent STAT3 dual phosphorylation inhibitor with an indole-containing tetra-aromatic heterocycle scaffold. STAT3-IN-32 exhibits STAT3 luciferase inhibition activity using HEK293T cells with an IC50 of 5.3 nM and ATP production inhibition activity using BxPC-3 cells with an IC50 of 4.2 nM. STAT3-IN-32 significantly blocks p-Tyr705 and p-Ser727 and causes the abrogation of the corresponding nuclear transcription and mitochondrial oxidative phosphorylation functions of STAT3 by targeting the STAT3 SH2 domain (KD=21.3 nM). STAT3-IN-32 exhibits significant suppressive effects in a pancreatic cancer xenograft model .
    STAT3-IN-32
  • HY-163526

    Ligands for Target Protein for PROTAC Cancer
    STAT3-IN-26 is the ligand for the target protein STAT3 in PROTAC STAT3 degrader-3 (HY-163502), which can be used for the synthesis of PROTACs .
    STAT3-IN-26
  • HY-123524

    STAT Cancer
    STAT3-IN-4 (compound B9) is a STAT3 inhibitor with Kd values for STAT3 (I634S/Q635G) and WT are 22.75 and 4.59 μM, respectively. STAT3-IN-4 can inhibit the proliferation of tumor cells .
    STAT3-IN-4
  • HY-161864

    STAT Inflammation/Immunology
    STAT3-IN-29 (Compound B20) is an inhibitor for STAT3. STAT3-IN-29 inhibits the proliferation of HaCaT cell with IC50 of 0.09 µM, ameliorates the IMQ-induced psoriasis in mouse models .
    STAT3-IN-29
  • HY-148706

    STAT Infection Cancer
    STAT3-IN-17 is a moderate STAT3 inhibitor (IC50=0.7 μM; HEK-Blue IL-6), with antiproliferative activity in HeLa cells. STAT3-IN-17 has good pharmacokinetic characteristics. STAT3-IN-17 also inhibits pyruvate-ferredoxin oxidoreductase (PFOR), and inhibits Helicobacter pylori .
    STAT3-IN-17
  • HY-159580

    STAT Cancer
    STAT3-IN-31 (compound K2071) is a STATtic-derived STAT3 and mitotic inhibitor. STAT3-IN-31 blocks mitotic progression and affects the formation of mitotic spindles. STAT3-IN-31 also affects glioblastoma cell migration and inhibits cell proliferation in tumor spheroids. STAT3-IN-31 is also able to induce glioblastoma senescence, inhibit the growth of Temozolomide (HY-17364)-resistant cells and the secretion of the pro-inflammatory cytokine monocyte chemoattractant protein MCP-1 .
    STAT3-IN-31
  • HY-117770

    STAT Others
    STAT3-IN-30 (compound 9c) is a STAT3 inhibitor with an EC50 of 13.8 μM .
    STAT3-IN-30
  • HY-100753
    STAT3-IN-1
    5+ Cited Publications

    STAT Apoptosis Cancer
    STAT3-IN-1 (compound 7d) is an excellent, selective and orally active STAT3 inhibitor, with IC50 values of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 (compound 7d) induces tumor cells apoptosis .
    STAT3-IN-1
  • HY-162828

    STAT HDAC Cancer
    STAT3/HDAC-IN-2 (compound 18) is a dual inhibitor of STAT3 and HDAC, inducing autophagy and apoptosis. STAT3/HDAC-IN-2 is an amphiphilic hydroxamic acid hybrid based on the natural product isopropanol lactone (IAL) and is a nanoscale anticancer agent. STAT3/HDAC-IN-2 can self-assemble in water to form nanoparticles, which have higher tumor tissue accumulation, cellular uptake and anticancer properties compared to the free state .
    STAT3/HDAC-IN-2
  • HY-151577

    STAT Apoptosis Cancer
    STAT3-SH2 domain inhibitor 1 is a potent Src Homology 2 (SH2) Domain of STAT3 (STAT3-SH2 domain) inhibitor with a Kd value of 1.57 μM. STAT3-SH2 domain inhibitor 1 inhibits STAT3 signaling transduction and transcriptional activation. STAT3-SH2 domain inhibitor 1 induces apoptosis in gastric cancer cells. STAT3-SH2 domain inhibitor 1 can be used in research of cancer .
    STAT3-SH2 domain inhibitor 1
  • HY-P10099

    STAT Cancer
    STAT3-IN-21, cell-permeable, negative control, a peptide, is a negative control for Stat3 activity detection .
    STAT3-IN-21, cell-permeable, negative control
  • HY-161351

    Akt STAT Apoptosis Cancer
    STAT3/AKT-IN-1 is a dual inhibitor for the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signalling pathway, exhibits antitumor activity against gastric cancer and induces cell apoptosis in SGC-7901 cells .
    STAT3/AKT-IN-1
  • HY-155942

    Others Others
    STAT3-IN-19 (compound 31) is a BRAF(V600E) inhibitor that has the function of inhibiting BRAF(V600E) activity. Its inhibitory mode and activity were determined through relevant screening and structural studies, and it has an inhibitory effect on MAPK signaling in melanoma cells.
    STAT3-IN-19
  • HY-P10115

    STAT Cancer
    APT STAT3 is a specific STAT3-binding peptide. APT STAT3 can bind STAT3 with high specificity and affinity (~231 nmol/L). APT STAT3 is a tractable agent for translation to target the broad array of cancers harboring constitutively activated STAT3 .
    APT STAT3
  • HY-153023

    PROTACs STAT Cancer
    PROTAC STAT3 degrader-2 is a selective and efficacious PROTAC degrader of STAT3 protein with a DC50 of 3.54 μM in Molm-16 Cell. PROTAC STAT3 degrader-2 has the potential for cancer research . PROTAC STAT3 degrader-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    PROTAC STAT3 degrader-2
  • HY-163502

    PROTACs STAT Cancer
    PROTAC STAT3 degrader-3 (S3D1) is a STAT3 PROTAC degrader with anticancer activity (Structural notes: (Blue: Cereblon ligand (HY-10984), Black: linker; Pink: Pentafluorobenzenesulfonamide(Me)-CH2-CONH-benzamide (HY-163526)) .
    PROTAC STAT3 degrader-3
  • HY-161136

    EGFR STAT Cancer
    EGFR/STAT3-IN-1 (Compound 5k) is a dual inhibitor of EGFR/STAT3 with IC50 values for EGFR and STAT3 are 41 and 3.34 nM, respectively. EGFR/STAT3-IN-1 has antitumor activity .
    EGFR/STAT3-IN-1
  • HY-157847

    STAT Cancer
    Phospho-STAT3-IN-2 (compound 4D) is a STAT3 inhibitor that effectively inhibits STAT3 phosphorylation. phospho-STAT3-IN-2 can significantly reduce tumor volume in mouse xenograft tumor models without drug toxicity to other organs and tissues .
    phospho-STAT3-IN-2
  • HY-168178

    HSP STAT Cardiovascular Disease
    Hsp110-STAT3 interaction-IN-2 (compound 10b) is a Hsp110-STAT3 interaction disruptor. Hsp110-STAT3 interaction-IN-2 can be used in pulmonary arterial hypertension (PAH) related research .
    Hsp110-STAT3 interaction-IN-2
  • HY-167839

    Others Cancer
    (R)-JAK2/STAT3-IN-1 is a GP130 D1 domain inhibitor with anti-tumor activity. (R)-JAK2/STAT3-IN-1 can inhibit the phosphorylation of JAK2 and STAT3. The affinity of (R)-JAK2/STAT3-IN-1 for GP130 protein is 3.8 μM. (R)-JAK2/STAT3-IN-1 effectively inhibits the viability and migration of tumor cells and promotes apoptosis .
    (R)-JAK2/STAT3-IN-1
  • HY-131194

    Interleukin Related Cancer
    JAK2/STAT3-IN-1 (compound (S)-10a) is a potent GP130 inhibitor with an IC50 of 3.04 µM. JAK2/STAT3-IN-1 shows anti-tumor activity .
    JAK2/STAT3-IN-1
  • HY-146066

    nAChR JAK STAT NO Synthase Inflammation/Immunology
    α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC50 value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .
    α7 nAchR-JAK2-STAT3 agonist 1
  • HY-161859

    VEGFR STAT Cancer
    VEGFR-2/STAT-3-IN-1 (Compound 9f) is a dual inhibitor for VEGFR-2 (IC50=26.3 nM) and STAT-3 (IC50=5.63 nM). VEGFR-2/STAT-3-IN-1 inhibits the proliferation of cancer cells PANC1 and PC3 with IC50 of 0.14 and 0.10 µM. VEGFR-2/STAT-3-IN-1 induces apoptosis in PC3 .
    VEGFR-2/STAT-3-IN-1
  • HY-Q43097

    Others Cardiovascular Disease
    Row174336 (compound 29) is a potent inhibitor of Hsp110-STAT3 interaction that shows antiproliferative activity against HPAEC cell line, with the IC50 of 22.67 μM .
    Hsp110-STAT3 interaction-IN-1
  • HY-107459

    (E/Z)-Tyrphostin AG490; (E/Z)-Tyrphostin B42

    EGFR STAT JAK Cancer
    (E/Z)-AG490 ((E/Z)-Tyrphostin AG490) is a racemic compound of (E)-AG490 and (Z)-AG490 isomers. (E)-AG490 (HY-12000) is a tyrosine kinase inhibitor that inhibits EGFR, Stat-3 and JAK2/3.
    (E/Z)-AG490

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: